CORAL SPRINGS, Florida, June 2, 2014 /PRNewswire/ --
Cannabis Sector updates & happenings as Marijuana companies make advancements to diversify cannabis based medicines; tests yield positive results to fight epilepsy: Cannabis Science (OTC: CBIS), GW Pharmaceuticals plc (NASDAQ: GWPH), ENDEXX Corp. (OTC: EDXC), Medbox, Inc. (OTC: MDBX) and Medical Marijuana, Inc. (OTC: MJNA)
Cannabis Science (OTC: CBIS) Takes Revolutionary Steps Toward Cannabis-Based Cancer Treatments Perhaps the only thing evolving faster than the global economy are the political and cultural trends of 21st Century American society, and one trend that has marked the last decade is a widespread shift toward the embracement of the healing and medicinal effects of cannabinoid-based therapies. Enter Cannabis Science, Inc. (OTC: CBIS), a biotech-that-could which has adopted a novel approach toward converting cultural cannabis trends into meaningful, long-lasting treatments for some of the most serious ailments affecting the human race, including cancer, AIDS, arthritis, and others. Cannabis Science employs a business model characterized by openness to partnership, as well as research and development fueled by thorough clinical trials and lead by a team of top biochemistry and pharmaceutical scientists. Biotech-hunting investors need look no further to snatch up a worthwhile piece of the vibrant cannabinoid market currently valued at up to $50 billion and rising as CBIS is currently trading at .092 per share with a volume of over 7M. To Read The Full CBIS Article, please go to http://tomorrowsbluechips.com/cannabis-science-cbis-takes-revolutionary-steps-cannabis-based-cancer-treatments/
As one of the first publicly-traded cannabinoid companies on the market, Cannabis Science takes the development of medicinal cannabinoid therapies to new frontiers in multiple ways, one of which is its promising INDs (Investigational New Drugs). Based on research published earlier this year, the Company has formulated CS-TATI-1, a cannabinoid extract that is thought to combat Epidemic Kaposi Sarcoma, a form of cancer brought on by certain strains of the HIV virus. Cannabis Science is also developing CS-S/BCC-1, a topically-applied cannabinoid extract that has been used to successfully treat skin cancer patients. The company expects to convert CS-S/BCC-1 into both over-the-counter and prescription treatments, with the first steps toward FDA-approval underway.
GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer.
ENDEXX Corp. (OTC: EDXC), a provider of innovative medical marijuana management and technology solutions, recently announced that it will be participating in investor conferences in several major cities to update and introduce investors to the value proposition they offer to the medical marijuana industry with its m3hub Seed to Sale tracking system and its Autospense™ inventory control and tracking system. In June, Endexx's senior management will be presenting at the following investor conferences: June 2: Canadian Investor Conference, Vancouver, Canada, June 3: Accredited Members (AMI) Small Cap/Micro Cap Conference, Colorado Springs, CO and June 30: 1st Annual WeedStock Investor Conference, Denver CO. Todd Davis, CEO of Endexx Corp., said, "The enthusiasm we've received from investors since launching the m3hub and Autospense™ earlier this year has been overwhelming. We are continuing to meet existing and potential new investors through multiple venues and are proud to share the progress we've made executing our strategy as we transition from a development company to a sales and growth enterprise."
Medbox, Inc. (OTC: MDBX), a leader in providing ancillary services to the alternative medicine industry, dispensary consulting services, and patented medicine dispensing systems to medical and retail industries, recently announced it has entered into an agreement with MJ Holdings, Inc. (OTC: MJNE), a publicly traded company that provides real estate financing and related solutions to licensed marijuana operators. Medbox will market MJ Holdings' real estate financial products and offerings to its roster of consulting clients and will direct all incoming real estate related opportunities to MJ Holdings. Dr. Bruce Bedrick, Medbox CEO stated, "Over the past several years Medbox has been engaged by more than 400 clients in six states to help entrepreneurs and investors secure licenses, identify locations and build-out dispensaries. We have developed unparalleled expertise as consultants and thought leaders in bringing a philosophy of security, safety and compliance to the legal marijuana industry."
Medical Marijuana, Inc. (OTC: MJNA) operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company's services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. On Friday, MJNA closed up 4.21% on over 3.4 million shares traded.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand seven hundred dollars for news coverage of the current article regarding Cannabis Science, Inc. by a non-affiliated third party.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC